PACIFIC-AMI: Factor XIa inhibitor asundexian on top of DAPT after acute MI

PACIFIC-AMI: Factor XIa inhibitor asundexian on top of DAPT after acute MI – #ESCCongress 2022

by michaelg August 29, 2022

Video by PCR via YouTube
Go to Source

Ali Nazmi Calik asks trial investigator John Alexander about the design and results of the PACIFIC-AMI phase 2 trial, which revealed no increase in bleeding versus placebo.

More news on the ESC Congress 2022 Interventional cardiology perspective on PCRonline: https://www.pcronline.com/News/Whats-new-on-PCRonline/2022/ESC-2022/PCRonline-ESC-Congress-2022

Go to Source

RTC - Radial versus femoral access for coronary… by Michaelg
T-PASS: Less than 1-month DAPT followed by… by Michaelg
INVICTUS - Rivaroxaban vs VKA for rheumatic atrial… by Michaelg
COVID-PACT - Antithrombotic therapy in critically… by Michaelg
ARREST trial: Expedited transfer to a cardiac arrest… by Michaelg
EARTH-STEMI: Complete revascularisation benefits in… by Michaelg

# education # innovation # innovative

PACIFIC-AMI: Factor XIa inhibitor asundexian on top of DAPT after acute MI – #ESCCongress 2022

Related Posts: